Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — J.P. Morgan 2026 Healthcare Conference
19 slides from Vitrolife Ab's conference presentation, Jan 14, 2026
Slide 1: J.P. Morgan 2026 Healthcare Conference
Vitrolife AB (publ) J.P. Morgan 2026 Healthcare Conference 2026-01-14 Bronwyn Brophy O'Connor Chief Executive Officer
Slide 2: Disclaimer
DISCLAIMER This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there i
Slide 3: Mission
Mission Be the leading global partner in reproductive health, striving for better treatment outcomes for patients Employees Sales 2024 Vitrolife AB (VITR) listed on ~ 1,100 $391M USD NASDAQ Stockholm Integrity Quality Innovation Collaboration 3
Slide 4: Vitrolife Group global presence
Vitrolife Group global presence 4
Slide 5: Well balanced from a geographic and portfolio perspective
Well balanced from a geographic and portfolio perspective Consumables APAC 40% 29% Americas 33% Genetics 41% Revenue by Revenue by geography* product groups* EMEA Technologies 38% 19% North America is number one focus market ~91% of sales from run rate business for the company. 5 *January-September
Slide 6: End to end high quality IVF portfolio
End to end high quality IVF portfolio 6
Slide 7: Significant market opportunity in reproductive health
Significant market opportunity in reproductive health Successful treatment outcomes ~33% *** 1 in 6 134 M Access and affordability constraining ~5% people globally is babies born annually** estimated cycle growth affected by infertility* < 1% via IVF growth in coming years *Source: World Health Orga
Slide 8: Africa is the only continent at or above replacement rate (2.1)
Africa is the only continent at or above replacement rate* (2.1) *Replacement rate refers to the percentage of a population replaced by births to maintain its size over time. 8 Human Fertility Database (2025); UN, World Population Prospects (2024)
Slide 9: Governments are taking more action to improve fertility rates
Governments are taking more action to improve fertility rates • Executive order issued to expand access to IVF and reduce its costs • "Baby bonuses" proposed to encourage higher birth rates • Employers encouraged to offer supplemental fertility care benefits • Fertility medication costs being reduce
Slide 10: Key IVF market dynamics driving growth for the Vitrolife Group
Key IVF market dynamics driving growth for the Vitrolife Group Growth in demand Increase IVF capacity and accessibility Clinics labor and skills shortage Automation and digitalization Consolidation of clinics Standardization and scalability Diverse portfolio to address differences in Regionalization
Slide 11: Vitrolife Group is committed to deliver sustainable profitable growth
Vitrolife Group is committed to deliver sustainable profitable growth Focus on five strategic priorities: 1. 2. 3. 4. 5. Own the platform Innovate to Accelerate growth Optimize Drive connecting expand leadership in key markets go-to-market operational products and model excellence services Long-term
Slide 12: Consistent track record of driving profitable growth
Consistent track record of driving profitable growth Sales EBITDA Net debt/EBITDA 3,609 MSEK 1,225 MSEK 3.2 $ 391M USD $ 133M USD 1.5 856 MSEK 303 MSEK 1 $ 100M USD $ 35M USD 0.7 2016 2024 2016 2024 2021 2022 2023 2024 12
Slide 13: Strong third quarter 2025 driven by North America performance
Strong third quarter 2025 driven by North America performance Third quarter 2025 Organic growth in local currencies Sales excluding discontinued business Gross margin 835 MSEK +5% 58.9% Highest revenue quarter Highest growth rate year to date Continued strong gross margin of the year to date EBITDA
Slide 14: As innovation leaders we continue to bring new products to the market
As innovation leaders we continue to bring new products to the market eWitness – Electronic Witnessing System for IVF Labs Now integrated with EmbryoScope as part of our platform Coming EmbryoCath soon EmbryoMap SNP Reagent Ultra RapidWarm Blast Sense needle - single lumen for reduced patient pain d
Slide 15: Driving automation and integration of the IVF journey to own the platform
Driving automation and integration of the IVF journey to own the platform Egg retrieval Sperm processing Insemination and ICSI Embryo culture and evaluation Transfer/Cryopreservation Sample and procedure tracking Equipment Quality Control Monitoring Consumables tracking Data analytics across the IVF
Slide 16: Uniquely positioned to serve different standards of care
The Vitrolife Group is uniquely positioned to serve different standards of care Two methods for embryo evaluation PGT-M PGT-A EMBRACE 1 Time-lapse technology-based assessment 2 Genetic assessment EmbryoScope® uses AI-based algorithms to analyze full course Analysis of embryo DNA to determine existen
Slide 17: Recent acquisitions and investments to advance our platform strategy
Recent acquisitions and investments to advance our platform strategy 17
Slide 18: Reasons to invest in Vitrolife AB (publ)
Reasons to invest in Vitrolife AB (publ) Underlying resilient market growth Ambitious strategy and long-term objectives Proven track record of profitable growth High quality brands linked with outstanding service and support Innovation and technology leader within fertility
Slide 19: Q&A
Q&A